Total knee replacement delayed with hylan G-F 20 use in patients with grade IV osteoarthritis

Journal of Managed Care Pharmacy

Volumn 13, Issue 2, 2007, Pages 113-121

  Waddell, David D ^a,b   Bricker, De Wayne C ^b  

^a Louisiana State University School of Medicine Shreveport   (United States)

^b NONE   (United States)

Author keywords

Hylan G F 20; Knee; Osteoarthritis; Pain; Total knee replacement

Indexed keywords

ANALGESIC AGENT; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; HYALURONIC ACID; HYDROCORTISONE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PENTAZOCINE;

AFRICAN AMERICAN; AGE DETERMINATION; BODY MASS; CAUCASIAN; CLINICAL TRIAL; COST BENEFIT ANALYSIS; CRYOTHERAPY; DAILY LIFE ACTIVITY; DEMOGRAPHY; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERANCE; ETHNICITY; FOLLOW UP; HUMAN; INJECTION SITE PAIN; JOINT SWELLING; KNEE PAIN; LOGISTIC REGRESSION ANALYSIS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OSTEOARTHRITIS; PHYSIOTHERAPY; REVIEW; SEX DIFFERENCE; SURVIVAL; TOTAL KNEE REPLACEMENT;

EID: 33947702035     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2007.13.2.113     Document Type: Review

References (53)

1. U.S. Dept. of Health &: Human Services, Centers for Disease Control and Prevention. Prevalence of disabilities and associated health conditions among adults - United States, 1999. MMWR. 2001;50:120-25.
2. Srikanth VK, Fryer JL, Zhai G, Winzenberg TM, Hosmer D, Jones G. A meta-analysis of sex differences prevalence, incidence, and severity of osteoarthritis. Osteoarthritis Cartilage. 2005;13:769-81.
3. Gupta S, Hawker GA, Laporte A, Croxford R, Coyte PC. The economic burden of disabling hip and knee osteoarthritis (OA) from the perspective of individuals living with this condition. Rheumatology (Oxford). 2005; 44:1531-37.
4. Altman RD, Hochberg MC, Moskowitz RW, Schnitzer TJ. Recommendations for the medical management of osteoarthritis of the hip and knee. Arthritis Rheum. 2000;43:1905-15.
5. Kozak LJ, Owings MF, Hall MJ. National Hospital Discharge Survey: 2001 annual summary with detailed diagnosis and procedure data. National Center for Health Statistics. Vital Health Stat. 2004;13.
6. Melzer D, Guralnik JM, Brock D. Prevalence and distribution of hip and knee joint replacements and hip implants in older Americans by the end of life. Aging Clin Exp Res. 2003;15:60-66.
7. The Institute of Orthopaedic Enlightenment. The Ortho FactBook. 2002-2003 Series, U.S. 3rd ed. Chagrin Falls, OH: Knowledge Enterprises, Inc.; 2002.
8. National Institutes of Health. NIH consensus statement on total knee replacement, December 8-10, 2003. J Bone Joint Surg Am. 2004;86-A:1328-35.
9. Buechel FF. The infected total knee arthroplasty: just when you thought it was over. J Arthroplasty. 2004;19(suppl 1):51-55.
10. Segawa H, Tsukayama DT, Kyle RF, Becker DA, Gustilo RB. Infection after total knee arthroplasty. A retrospective study of the treatment of eighty-one infections. J Bone Joint Surg Am. 1999;81-A:1434-45.
11. Lombardi AV, Mallory TH, Fada RA, et al. Simultaneous bilateral total knee arthroplasties: who decides? Clin Orthop Rel Res. 2001;392:319-29.
12. Weaver F, Hynes D, Hopkinson W, et al. Preoperative risks and outcomes of hip and knee arthroplasty in the Veterans Health Administration. J Arthroplasty. 2003;18:693-708.
13. Ginsberg JS, Turkstra F, Bullet HR, Mackinnon B, Magier D, Hirsh J. Postthrombotic syndrome after hip or knee arthroplasty: a cross-sectional study. Arch Intern Med. 2000;160:669-72.
14. Saleh KJ, Hoeffel DP, Kassim RA, Burstein G. Complications after revision total knee arthroplasty. J Bone Joint Surg Am. 2003;85-A(suppl 1):S71-S74.
15. Kim YH, Oh SH, Kim JS. Incidence and natural history of deep-vein thrombosis after total hip arthroplasty. A prospective and randomised clinical study. J Bone Joint Surg Br. 2003;85-B:661-65.
16. Kim YH. Incidence of fat embolism syndrome after cemented or cementless bilateral simultaneous and unilateral total knee arthroplasty J Arthroplasty. 2001;16:730-39.
17. Ohdera T, Tokunaga M, Hiroshima S, Yoshimoto E, Matsuda S. Recurrent hemarthrosis after knee joint arthroplasty: etiology and treatment. J Arthroplasty. 2004;19:157-61.
18. Ortiguera CJ, Berry DJ. Patellar fracture after total knee arthroplasty. J Bone Joint Surg Am. 2002;84-A:532-40.
19. Dalury DF, Jiranek WA. The incidence of heterotopic ossification after total knee arthroplasty. J Arthroplasty. 2004;19(suppl 1):447-52.
20. Toyoda T, Matsumoto H, Tsuji I, Kinouchi J, Fujikawa K. Heterotopic ossification after total knee arthroplasty. J Arthroplasty. 2003;18:760-64.
21. Laskin RS, Beksac B. Stiffness after total knee arthroplasty. J Arthroplasty. 2004;19(suppl 2):41-46.
22. Bong MR, Di Cesare PE. Stiffness after total knee arthroplasty. J Am Acad Orthop Surg. 2004;12:164-71.
23. Idusuyi OB, Morrey BF. Peroneal nerve palsy after total knee arthroplasty. Assessment of predisposing and prognostic factors. J Bone Joint Surg Am. 1996;78-A:177-84.
24. Da Silva MS, Sobel M, The Surgeons of the Southern Association of Vascular Surgery. Popliteal vascular injury during total knee arthroplasty. J Surg Res. 2003;109:170-74.
25. Langkamer VG. Local vascular complications after knee replacement: a review with illustrative case reports. Knee. 2001;8:259-64.
26. Bhattacharyya T, Iorio R, Healy WL. Rate of and risk factors for acute inpatient mortality after orthopaedic surgery. J Bone Joint Surg. 2002;84-A:562-72.
27. Gill GS, Mills D, Joshi AB. Mortality following primary total knee arthroplasty. J Bone Joint Surg Am. 2003;85-A:432-35.
28. Parvizi J, Sullivan TA, Trousdale RT, Lewallen DG. Thirty-day mortality after total knee arthroplasty. J Bone Joint Surg Am. 2001;83-A:1157-61.
29. Nunley RM, Lachiewicz PF. Mortality after total hip and knee arthroplasty in a medium-volume university practice. J Arthroplasty. 2003;18:278-85.
30. Bullock DP, Sporer SM, Shirreffs TG. Comparison of simultaneous bilateral with unilateral total knee arthroplasty in terms of perioperative complications. J Bone Joint Surg. 2003;85-A:1981-86.
31. Wobig M, Dickhut A, Maier R, Vetter G. Viscosupplementation with hylan G-F 20: a 26-week controlled trial of efficacy and safety in the osteoarthritic knee. Clin Ther 1998;20:410-23.
32. Scale D, Wobig M, Wolpert W. Viscosupplementation of osteoarthritic knees with hylan: a treatment schedule study. Curr Ther Res. 1994;55:220-32.
33. Adams ME. An analysis of clinical studies of the use of crosslinked hyaluronan, hylan, in the treatment of osteoarthritis. J Rheumatol. 1993;20: 16-18.
34. Adams ME, Atkinson MH, Lussier AJ, et al. The role of viscosupplementation with hylan G-F 20 (Synvisc) in the treatment of osteoarthritis of the knee: a Canadian multicenter trial comparing hylan G-F 20 alone, hylan G-F 20 with non-steroidal anti-inflammatory drugs (NSAIDs) and NSAIDs alone. Osteoarthritis Cartilage. 1995;3:213-25.
35. Raynauld JP, Torrance GW, Band PA, et al. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (part 1 of 2): clinical results. Osteoarthritis Cartilage. 2002;10:506-17.
36. Wobig M, Beks P, Dickhut A, Maier R, Vetter G. Open-label multicenter trial of the safety and efficacy of viscosupplementation with hylan G-F 20 (Synvisc) in primary osteoarthritis of the knee. J Clin Rheumatol. 1999;5:S24-S31.
37. Lussier A, Cividino AA, McFarlane CA, Olszynski WP, Potashner WJ, De Medicis R. Viscosupplementation with hylan for the treatment of osteoarthritis: findings from clinical practice in Canada. J Rheumatol. 1996;23:1579-85.
38. Waddell DD, Bucker D. Hylan G-F 20 reduces the probability of progression to total knee replacement in knee osteoarthritis. Arthritis Rheum. 2001; 44:S49.
39. Bell M, Fallaha M, Lenczner E, Ranger P, Welsh P. Viscosupplementation with hylan G-F 20 in total knee replacement candidates: an effective pain management therapy that may delay surgery. Osteoarthritis Cartilage. 1999;7 (suppl A):S30.
40. Waddell D, Rein A, Panarites C, Coleman M, Weiss C. Cost implications of introducing an alternative treatment for patients with osteoarthritis of the knee in a managed care setting. Am J Manag Care. 2001;7:981-91.
41. Waddell D, Estey D, Bricker DC, Marsala A. Viscosupplementation under fluoroscopic control. Am J Med Sports. 2001;4:237-241,249.
42. Drug Topics Red Book [CD-ROM]. November 2006. Montvale, NJ: Medical Economics.
43. National average physician reimbursement rates. Federal Register. 2006; 70:223.
44. U.S. Dept. of Health & Human Services, Centers for Medicare & Medicaid Services. October 2006 ASP pricing file. Available at: http://www.cms.hhs.gov/McrPartBDrugAvgSalesPrice/02_aspfiles.asp. Accessed October 19, 2006.
45. Synvisc (hylan G-F 20) [product information]. Ridgefield, NJ: Genzyme Biosurgery; 2003.
46. Waddell DD, Cefalu CA, Bricker DC. An open-label study of a second course of hylan G-F 20 for the treatment of pain associated with knee osteoarthritis. Curr Med Res and Opin. 2003;19:499-507.
47. Waddell DD, Cefalu CA, Bricker DC. A second course of hylan G-F 20 for the treatment of osteoarthritic knee pain: 12-month patient follow-up. J Knee Surg. 2005;18:7-15.
48. Waddell DD, Bricker DC. Hylan G-F 20 tolerability with repeat treatment in a large orthopedic practice: a retrospective review. J Surg Orthop Adv. 2006;15:53-59.
49. Mont MA, Lee CW, Sheldon M, Lennon WC, Hungerford DS. Total knee arthroplasty in patients ≤50 years old. J Arthroplasty. 2002; 17:538-43.
50. Brander VA, Malhotra S, Jet J, Heinemann AW, Stulberg SD. Outcomes of hip and knee arthroplasty in persons aged 80 years and older. Clin Orthop Rel Res. 1997;345:67-78.
51. Pagnano MW, McLamb LA, Trousdale RT. Total knee arthroplasty for patients 90 years of age and older. Clin Orthop. 2004;179-83.
52. Waddell DD, Bricker D. Clinical experience with the effectiveness and tolerability of hylan G-F 20 in 1047 patients with osteoarthritis of the knee. J Knee Surg. 2006;19:19-27.
53. Waddell DD. The tolerability of viscosupplementation: low incidence and clinical management of local adverse events. Curr Med Res Opin. 2003;19: P1-P6.